Loncar Cancer Immunotherapy ETF (CNCR)
|Ex-Dividend Date||Dec 29, 2021|
|Day's Range||15.39 - 15.86|
|Inception Date||Oct 13, 2015|
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Top 10 Holdings37.32% of assets
|Dec 29, 2021||$1.8533352||Dec 31, 2021|
|Dec 30, 2020||$0.2881193||Jan 4, 2021|
|Dec 28, 2017||$0.35019938||Jan 2, 2018|
|Dec 29, 2015||$0.10551286||Jan 4, 2016|
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. The ...
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.
U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.